13 results about "Immunoglobulin chain" patented technology

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivering anti-HIV antibody agents and related techniques (e.g., components thereof and / or methods related thereto). In addition to this, the present disclosure also provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of anti-HIV antibody agents and related technologies (e.g., components thereof and / or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.

The present disclosure provides compositions (e.g., pharmaceutical compositions) and related technology (e.g., components thereof and / or methods related thereto) for delivery of anti-HIV antibody agents. The present disclosure provides, among other things, polyribonucleotides encoding immunoglobulin chains of anti-HIV antibody agents. The present disclosure recognizes that HIV mutates rapidly. The highly mutating nature of HIV virions allows them to escape host immune and / or therapeutic pressures.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivering anti-HIV antibody agents and related techniques (e.g., components thereof and / or methods related thereto). In addition to this, the present disclosure also provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.

Collapsin reaction-mediating protein 2 (CRMP2) is established as a therapeutic target in neurodegenerative diseases. Novel human-derived anti-CRMP2 antibodies, as well as their fragments, derivatives, and variants, are provided. Polynucleotides, vectors, host cells, and kits related to CRMP2-specific antibodies are also provided. These antibodies, immunoglobulin chains, and their binding fragments, derivatives, and variants can be used in pharmaceutical compositions for CRMP2-targeted therapy.

Antibodies comprising unpaired variable domains, e.g., heavy chain variable (VH) domains, for binding antigen. Antibody comprising two immunoglobulin (Ig) chains, wherein a first Ig chain comprises a variable domain and a constant domain, and a second Ig chain comprises a constant domain, wherein the second Ig chain lacks a variable domain, leaving the variable domain of the first Ig chain unpaired. The antibody may comprise two Ig heavy chains and two Ig light chains, each heavy chain comprising a VH domain and a constant region comprising a CH1 domain, and each light chain comprising a CL domain, wherein one or both light chains lack a VL domain, thereby leaving one or both VH domains unpaired. Non-human animals (e.g., mice) engineered to produce antibodies having unpaired VH domains, involving deletion of sequence coding for light chain variable (VL) domains. Use of unpaired VH domains to generate antigen-binding molecules.

Brain failure response regulatory protein 2 (CRMP2) is established as a therapeutic target for neurodegenerative disorders. Novel human anti-CRMP2 antibodies and fragments, derivatives and variants thereof are provided. Polynucleotides, vectors, host cells, and kits associated with the CRMP2 specific antibodies are also provided. The antibodies, immunoglobulin chains, and binding fragments, derivatives, and variants thereof are useful in pharmaceutical compositions for targeted therapy against CRMP2.

Provided are novel human-derived monoclonal neutralizing Nogo-A specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Polynucleotides, vectors, host cells and kits related to the Nogo-A specific antibodies are also provided. The antibodies, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for Nogo-A targeted immunotherapy and diagnosis, respectively.

The present disclosure provides methods for identifying cognate pairs of genes or gene fragments that are co-expressed in cells such as immunoglobulin heavy and light chains. The methods include plating predefined number of cells per well, sequencing the immunoglobulin chains and identifying cognate pairs based on scores assigned to each pair of immunoglobulin heavy and light chains.

There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-23, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1 comprises a sequence sharing 60% or greater sequence identity with SEQ ID NO: 1, CDR2 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 2 and CDR3 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 3.

The invention discloses a marker group for evaluating sensitivity of bicitinib combined with narrow-spectrum medium-wave ultraviolet rays in treatment of leucoderma, a substance for detecting the marker group, a kit and an evaluation method. The marker group contains a plasma biomarker P selectin (SELP), an apolipoprotein A4 (APOA4), a mannan binding lectin associated serine protease 1 (MASP1), and a urine biomarker immune globulin J chain (IGJ) and an interleukin 18 binding protein (IL-18BP). By detecting the expression change of the group of markers in a sample before and after treatment and combining with a vitiligo area scoring index (VASI), the treatment sensitivity of a patient can be accurately evaluated, an individualized scheme can be made in an assisted manner, the blank of the combination therapy curative effect evaluation marker is filled, and the combination therapy curative effect evaluation marker has a relatively high clinical transformation value.

This disclosure provides compositions (e.g., pharmaceutical compositions) for delivering anti-HIV antibody agents, as well as related technologies (e.g., their components and / or methods). In addition, this disclosure provides polynucleotides encoding multiple immunoglobulin chains of anti-HIV antibody agents.

The present disclosure relates to cell-type restricted or -specific inhibition of transforming growth factor-beta receptor 2-mediated responses. In particular there is provided for a conjugate, for example a fusion protein, comprising a first moiety, which is an immunoglobulin chain variable domain which is capable of specifically binding transforming growth factor-beta receptor 2, and at least a second moiety capable of binding a target, for example, expressed on the cell surface of a target cell that expresses transforming growth factor-beta receptor 2, and wherein the first moiety on its own, i.e. in the absence of the second moiety, is unable to inhibit TGFB signaling in such cell. Also provided is for the treatment of a disease or condition with the conjugate.